Intraoperative imaging technology to maximise extent of resection for glioma by Jenkinson, Michael D et al.
Cochrane Database of Systematic Reviews
Intraoperative imaging technology tomaximise extent of
resection for glioma (Review)
Jenkinson MD, Barone DG, Bryant A, Vale L, Bulbeck H, Lawrie TA, Hart MG, Watts C
Jenkinson MD, Barone DG, Bryant A, Vale L, Bulbeck H, Lawrie TA, Hart MG, Watts C.
Intraoperative imaging technology tomaximise extent of resection for glioma.
Cochrane Database of Systematic Reviews 2018, Issue 1. Art. No.: CD012788.
DOI: 10.1002/14651858.CD012788.pub2.
www.cochranelibrary.com
Intraoperative imaging technology tomaximise extent of resection for glioma (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
6BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
17ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
23DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
26ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
26REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
29CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
43DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
43ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
44APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
49CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
49DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
50SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
50DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
iIntraoperative imaging technology to maximise extent of resection for glioma (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Intraoperative imaging technology to maximise extent of
resection for glioma
Michael D Jenkinson1 , Damiano Giuseppe Barone2, Andrew Bryant3, Luke Vale3, Helen Bulbeck4, Theresa A Lawrie5, Michael G
Hart6, Colin Watts6
1Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK. 2Department of Clinical Neurosciences,
University of Cambridge School of Clinical Medicine, Cambridge, UK. 3Institute of Health& Society, Newcastle University, Newcastle
upon Tyne, UK. 4Director of Services, brainstrust, Cowes, UK. 5Cochrane Gynaecological, Neuro-oncology and Orphan Cancer
Group, 1st Floor Education Centre, Royal United Hospital, Bath, UK. 6Academic Division of Neurosurgery, Department of Clinical
Neurosciences, Addenbrookes Hospital, Cambridge, UK
Contact address: Michael D Jenkinson, Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Lower Lane,
Liverpool, Merseyside, L9 7LJ, UK. Michael.Jenkinson@liverpool.ac.uk.
Editorial group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group.
Publication status and date: New, published in Issue 1, 2018.
Citation: JenkinsonMD, Barone DG, Bryant A, Vale L, BulbeckH, Lawrie TA,HartMG,Watts C. Intraoperative imaging technology
to maximise extent of resection for glioma. Cochrane Database of Systematic Reviews 2018, Issue 1. Art. No.: CD012788. DOI:
10.1002/14651858.CD012788.pub2.
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Extent of resection is considered to be a prognostic factor in neuro-oncology. Intraoperative imaging technologies are designed to help
achieve this goal. It is not clear whether any of these sometimes very expensive tools (or their combination) should be recommended
as standard care for people with brain tumours. We set out to determine if intraoperative imaging technology offers any advantage in
terms of extent of resection over standard surgery and if any one technology was more effective than another.
Objectives
To establish the overall effectiveness and safety of intraoperative imaging technology in resection of glioma. To supplement this review
of effects, we also wished to identify cost analyses and economic evaluations as part of a Brief Economic Commentary (BEC).
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 7, 2017), MEDLINE (1946 to June, week 4,
2017), and Embase (1980 to 2017, week 27). We searched the reference lists of all identified studies. We handsearched two journals, the
Journal of Neuro-Oncology and Neuro-oncology, from 1991 to 2017, including all conference abstracts. We contacted neuro-oncologists,
trial authors, and manufacturers regarding ongoing and unpublished trials.
Selection criteria
Randomised controlled trials evaluating people of all ages with presumed new or recurrent glial tumours (of any location or histology)
from clinical examination and imaging (computed tomography (CT) or magnetic resonance imaging (MRI), or both). Additional
imaging modalities (e.g. positron emission tomography, magnetic resonance spectroscopy) were not mandatory. Interventions included
intraoperativeMRI (iMRI), fluorescence-guided surgery, ultrasound, and neuronavigation (with or without additional image processing,
e.g. tractography).
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Data collection and analysis
Two review authors independently assessed the search results for relevance, undertook critical appraisal according to known guidelines,
and extracted data using a prespecified pro forma.
Main results
We identified four randomised controlled trials, using different intraoperative imaging technologies: iMRI (2 trials including 58
and 14 participants, respectively); fluorescence-guided surgery with 5-aminolevulinic acid (5-ALA) (1 trial, 322 participants); and
neuronavigation (1 trial, 45 participants). We identified one ongoing trial assessing iMRI with a planned sample size of 304 participants
for which results are expected to be published around autumn 2018. We identified no trials for ultrasound.
Meta-analysis was not appropriate due to differences in the tumours included (eloquent versus non-eloquent locations) and variations
in the image guidance tools used in the control arms (usually selective utilisation of neuronavigation). There were significant concerns
regarding risk of bias in all the included studies. All studies included people with high-grade glioma only.
Extent of resection was increased in one trial of iMRI (risk ratio (RR) of incomplete resection 0.13, 95% confidence interval (CI)
0.02 to 0.96; 1 study, 49 participants; very low-quality evidence) and in the trial of 5-ALA (RR of incomplete resection 0.55, 95%
CI 0.42 to 0.71; 1 study, 270 participants; low-quality evidence). The other trial assessing iMRI was stopped early after an unplanned
interim analysis including 14 participants, therefore the trial provides very low-quality evidence. The trial of neuronavigation provided
insufficient data to evaluate the effects on extent of resection.
Reporting of adverse events was incomplete and suggestive of significant reporting bias (very low-quality evidence). Overall, reported
events were low in most trials. There was no clear evidence of improvement in overall survival with 5-ALA (hazard ratio 0.83, 95%
CI 0.62 to 1.07; 1 study, 270 participants; low-quality evidence). Progression-free survival data were not available in an appropriate
format for analysis. Data for quality of life were only available for one study and suffered from significant attrition bias (very low-quality
evidence).
Authors’ conclusions
Intra-operative imaging technologies, specifically iMRI and 5-ALA, may be of benefit in maximising extent of resection in participants
with high grade glioma. However, this is based on low to very low quality evidence, and is therefore very uncertain. The short- and
long-term neurological effects are uncertain. Effects of image-guided surgery on overall survival, progression-free survival, and quality
of life are unclear. A brief economic commentary found limited economic evidence for the equivocal use of iMRI compared with
conventional surgery. In terms of costs, a non-systematic review of economic studies suggested that compared with standard surgery use
of image-guided surgery has an uncertain effect on costs and that 5-aminolevulinic acid was more costly. Further research, including
studies of ultrasound-guided surgery, is needed.
P L A I N L A N G U A G E S U M M A R Y
Image-guided surgery for brain tumours
Background
Surgery has a key role in the management of many types of brain tumour. Removing as much tumour as possible is very important, as
in some types of brain tumour this can help patients to live longer and to feel better. However, removing a brain tumour may in some
cases be difficult because the tumour either looks like normal brain tissue or is near brain tissue that is needed for normal functioning.
New methods of seeing tumours during surgery have been developed to help surgeons better identify tumour from normal brain tissue.
Question
1. Is image-guided surgery more effective at removing brain tumours than surgery without image guidance?
2. Is one image guidance technology or tool better than another?
Study characteristics
Our search strategy is up to date as of July 2017. We found four trials looking at three different types of tools to help improve the
amount of tumour that is removed. The tumour being evaluated was high-grade glioma. Imaging interventions used during surgery
included:
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• magnetic resonance imaging (iMRI) during surgery to assess the amount of remaining tumour;
• fluorescent dye (5-aminolevulinic acid) to mark out the tumour; or
• imaging before surgery to map out the location of a tumour, which was then used at the time of surgery to guide the surgery
(neuronavigation).
All the studies had compromised methods, which could mean their conclusions were biased. Other studies were funded by the
manufacturers of the image guidance technology being evaluated.
Key results
We found low- to very low-quality evidence that use of image-guided surgery may result in more of the tumour being removed surgically
in some people. The short- and long-term neurological effects are uncertain. We did not have the data to determined whether any of
the evaluated technologies affect overall survival, time until disease progression, or quality of life. There was very low-quality evidence
for neuronavigation, and we identified no trials for ultrasound guidance. In terms of costs, a non-systematic review of economic studies
suggested that compared with standard surgery use of image-guided surgery has an uncertain effect on costs and that 5-aminolevulinic
acid was more costly than conventional surgery.
Quality of the evidence
Evidence for intraoperative imaging technology for use in removing brain tumours is sparse and of low to very low quality. Further
research is needed to assess three main questions.
1. Is removing more of the tumour better for the patient in the long term?
2. What are the risks of causing a patient to have worse symptoms by taking out more of the tumour?
3. How does resection affect a patient’s quality of life?
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
iMRI image-guided surgery compared to standard surgery for high-grade glioma
Patient or population: high-grade glioma
Settings: specialist centres
Intervention: iMRI image-guided surgery (based on post-operat ive MRI)
Comparison: standard surgery
Outcomes Illustrative comparative risk* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Image-guided surgery
Extent of resection:
complete resection
321 per 100 4 per 100
(1 to 31)
RR 0.13 (0.02 to 0.96) 49 part icipants
(1 study)
⊕©©©1,2,3
very low
Small t rial of highly se-
lected part icipants with
potent ial bias in alloca-
t ion and performance.
One other trial reported
this outcome but did
not contribute towards
the analysis
Adverse events Inadequately and inconsistent ly reported in the trial ⊕©©©4
very low
Adverse events were re-
ported in an inconsis-
tent manner and not ac-
cording to the manner
prespecif ied in our pro-
tocol. Addit ionally, we
were mainly interested
in ident if ying serious
adverse events, which
were inadequately re-
ported
4
In
tra
o
p
e
ra
tiv
e
im
a
g
in
g
te
c
h
n
o
lo
g
y
to
m
a
x
im
ise
e
x
te
n
t
o
f
re
se
c
tio
n
fo
r
g
lio
m
a
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Overall survival Not est imable ⊕©©©4
very low
Not reported by trial au-
thors so graded as very
low quality evidence
Progression- free sur-
vival
Not est imable ⊕©©©4
very low
Progression-f ree sur-
vival or t ime to pro-
gression was not ade-
quately reported in the
trial
Quality of life Not est imable ⊕©©©4
very low
Quality of lif e was not
reported in the trial
* The basis for the assumed risk is only based on individual trials as only single trial reports were available. The corresponding risk (and its 95% conf idence interval) is based
on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; iMRI: intraoperat ive magnetic resonance imaging; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Expressed in terms of risk of incomplete resect ion (bad outcome).
2Small t rial so quality of the evidence downgraded by one level.
3Highly selected part icipants with potent ial bias in allocat ion and performance as well as in other ’Risk of bias’ domains, thus
downgraded by two levels.
4Outcome was not reported (or inadequately reported for meaningful conclusions to be drawn), therefore giving lowest quality
of evidence judgement.
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B A C K G R O U N D
Description of the condition
Tumours of the central nervous system constitute a large group
characterised by a wide range of genetic, histological, and func-
tional diversity (Louis 2016). Secondary brain tumours or metas-
tases are the most common, accounting for almost half of all cen-
tral nervous system tumours. Primary brain tumours typically oc-
cur as some variation of a glioma, so called because they arise from
the supporting glial cell architecture; of these, glioblastoma is the
most frequent and most malignant histological subtype (Ohgaki
2009).
Brain tumours may present with headaches, neurological deficits,
or seizures, alone or in combination. Treatment choices include
surgery (usually biopsy or resection), radiotherapy, and chemo-
therapy. National guidelines recommend that management of a
central nervous system tumour should be discussed by a multidis-
ciplinary team and individually tailored to patient needs (NICE
2006).
Description of the intervention
Intraoperative magnetic resonance imaging (iMRI) involves the
use of an MRI during the actual operation to assess where there
remains tumour that can be removed. Details on the fine anatom-
ical structure of soft tissues provided by this technique have rev-
olutionised the field of neuroscience, but the equipment is ex-
pensive and bulky. Intraoperative MRI requires a specific portable
MRI scanner or a parallel stationary MRI scanner that is available
for use in an adjacent diagnostic room. Acquisition of iMRI is
aimed at providing high-definition, easily interpreted images for
real-time assessment of tumour resection, allowing the possibility
of immediate further resection during the same operative session
(Black 1997; Seifert 2003). Uptake has been limited by low field
strength scanners, which are associated with poor image quality,
extended surgical time, and substantial capital costs.
Neuronavigation refers to representing a spatial position on the
patient in imaging data. Preoperative imaging is used to localise a
lesion, perform a tailored craniotomy, and guide resection. Post-
operative MRI is performed to determine the extent of resection.
A major limitation of this technique is the phenomenon of intra-
operative brain shift, whereby the preoperative anatomy is altered
during tumour resection and accuracy is consequently reduced.
Advantages include the potential to use advanced imaging (func-
tional MRI or tractography, for example) to define eloquent or
invaded tissues.
Ultrasonography, performed in two or three dimensions (2D
or 3D, respectively), enables visualisation of structures through
recorded reflections of echoes of ultrasonic wave pulses (frequency
> 20 MHz) directed into the tissue of interest. Freehand move-
ment of an ultrasonography probe allows determination of image
volume in 3D. Volumetric reconstruction allows neuronavigation
accurate to within 1.4mm.Updated 3D ultrasonography volumes
can be created at any time during surgery. Advantages include rel-
ative affordability, easy repeatability, non-invasiveness, lack of ra-
diation, and the option for use in combination with other intraop-
erative technologies; the main disadvantage is operator variability,
because efficacy depends on skill and experience (Unsgaard 2006).
Fluorescence-guided surgery uses 5-aminolevulinic acid (5-ALA)
as a natural biochemical precursor of haemoglobin that elicits syn-
thesis and accumulation of fluorescent porphyrins preferentially
in mitotically active tissue (Regula 1995). Porphyrin fluorescence
can be visualised with the use of a modified microscope and ultra-
violet light with the aim of identifying neoplastic tissue (Stummer
1998; Stummer 2000). Limitations include lack of a clear bound-
ary between neoplastic and eloquent tissue, and variability in up-
take of 5-ALA depending on tumour characteristics. Distinct from
iMRI and 3D ultrasonography, both of which involve little cost
after the initial outlay, is the cost per patient of each dose of 5-
ALA, in addition to the requirement for a specific compatible op-
erating microscope. Adverse events include hypotension, nausea,
photosensitivity, and photodermatosis.
How the intervention might work
The extent of surgical resection is considered to be one of sev-
eral important prognostic factors in neuro-oncology. For some tu-
mours this is clearly established, while for others the relationship
is less clear (Hart 2011). Although high-quality evidence is lack-
ing, estimated benefits of gross total resection include a possible
extension of survival from around 11 months to 14 months in
glioblastoma, and from around 60 months to 90 months in low-
grade glioma, albeit based in highly selected patients in non-ran-
domised trials (Watts 2016). Limitations to the extent of surgical
resection are related to difficulty in identifying residual tumour
intraoperatively and proximity of the tumour to eloquent brain.
Intraoperative imaging technologies have been developed to aid
detection of residual tumour with the aim of extending resection.
This information can be used by the surgeon to optimise resec-
tion, thereby potentially improving prognosis. Overall, prognosis
for people with high-grade glioma and low-grade glioma depends
on several factors of which extent of resection is one, and the im-
portance of this prognostic factor may vary in different subgroups
of these patients.
Why it is important to do this review
Maximising the extent of resection comes with the risk of en-
croaching upon eloquent brain. Potential benefits of more exten-
sive tumour resection must be balanced against risks of causing
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newneurological deficits and reduced quality of life. This demands
an objective assessment of risks and benefits for each technology.
Experience with each different technology is often limited within
individual units. Often, technologies are seen as an evolution of es-
tablished techniques and are not subjected to the rigorous scrutiny
required for other new therapies, therefore evidence is potentially
limited to small single-institution case series. Direct comparisons
between different intraoperative imaging technologies are neces-
sary to limit overexpenditure on redundant technology and po-
tential risk to patients.
This review aims to serve as a single comprehensive resource de-
scribing level of evidence and effectiveness for each technology.
O B J E C T I V E S
To establish the overall effectiveness and safety of intraoperative
imaging technology in resection of glioma. To supplement this
review of effects, we also wished to identify cost analyses and
economic evaluations as part of a Brief Economic Commentary
(BEC).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
This review included people of all ages with presumed new or re-
current glial tumours (of any location or histology) from clinical
examination and imaging (computed tomography (CT) or MRI,
or both). Additional imaging modalities (e.g. positron emission
tomography, magnetic resonance spectroscopy) were not manda-
tory.
Types of interventions
Any of the following interventions could be compared with each
other as well as within each intervention class (e.g. different forms
of fluorescence-guided surgery).
• Intraoperative MRI (iMRI): defined as using a portable or
fixed scanner (and moving scanner or patient, respectively) to
acquire image data while the patient remains under anaesthesia.
Can be integrated with neuronavigation (see below).
• Neuronavigation or image guidance: defined as a system
that integrates preoperative or intraoperative image data and
creates a translation map between ’world space’ and ’image space’
to allow co-registration of imaging and patient anatomy.
• Intraoperative ultrasonography (2D or 3D): defined as a
system that uses freehand movement of an ultrasonography
probe over the region of interest and subsequently generates a
volumetric reconstruction allowing intraoperative
neuronavigation.
• Fluorescence-guided surgery: defined as administration of a
contrast agent and intraoperative visualisation with the use of
ultraviolet light (usually a specific mode of an operating
microscope).
Types of outcome measures
Primary outcomes
1. Extent of resection: as shown on follow-up imaging.
Historically this has been broadly divided into complete
resection, partial resection, and biopsy. Updated response criteria
are available to enable dichotomising this into measurable and
non-measurable disease for contrast-enhancing lesions (Wen
2010). Volumetric assessment is a better method of assessment in
terms of accuracy and objectivity but requires additional imaging
processing time and is not used routinely in many NHS
(National Health Service) centres. Intraoperative evaluation of
extent of resection by the operating surgeon is a biased and
unverifiable method and therefore is not acceptable (Hensen
2008). We planned to use percentage resection, residual, mean
volumes, and percentage of total/non-total resection.
2. Adverse events: type (as defined by MedDRA (Medical
Dictionary for Regulatory Authorities) criteria) and timing
(MedDRA 2008). Examples include haematoma, wound
complications, infection (and site), cerebrospinal fluid leak,
oedema, seizures, and general medical complications. Additional
procedures required for complications should be noted. Both the
total number of complications and the number of complications
per participant should be stated.
Secondary outcomes
1. Overall survival: length of time (in days, weeks, or months)
from randomisation to death (from any cause).
2. Progression-free survival (PFS): use of open and thorough
criteria to define recurrence according to clinical symptoms,
imaging, and increase in steroid therapy (Wen 2010).
3. Quality of life (QoL): use of a reliable and objective grading
measure such as the EORTC QLQ-C30/BN-20 (European
Organisation for Research and Treatment of Cancer QoL
assessment specific to brain neoplasms) and FACT-BrS
(Functional Assessment of Cancer Therapy - brain subscale)
(Mauer 2008)
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We planned to present a ’Summary of findings’ table reporting the
following outcomes, which are listed in order of priority (see Data
synthesis).
1. Extent of resection
2. Adverse events
3. Overall survival
4. PFS
5. QoL
Search methods for identification of studies
Non-English language journals were eligible for inclusion.
Electronic searches
We searched the following electronic databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL; Issue 7, 2017) in the Cochrane Library.
• MEDLINE (Ovid) (1946 to June week 4 2017).
• Embase (Ovid) (1980 to 2017 week 27).
Search strategies for identification of RCTs in CENTRAL, MED-
LINE, and Embase are depicted in Appendix 1; Appendix 2;
Appendix 3, and for the brief economic commentary for MED-
LINE in Appendix 4 and Embase in Appendix 5.
Searching other resources
We searched the references of all identified studies for additional
trials.
Handsearching
We handsearched the Journal of Neuro-Oncology, Neuro-oncology,
Journal of Neurosurgery, and Neurosurgery from 1991 to 2017, to
identify trials that may not have been included in the electronic
databases, including a search of all conference abstracts published
in these journals.
Personal communication
We contacted neuro-oncology experts to obtain information on
current or pending RCTs as well as authors to clarify whether their
study met the inclusion criteria or to request additional informa-
tion where aspects of the publication were unclear.
We contacted the following neuro-oncology experts for informa-
tion on any current or pending RCTs: Professor Mitchel S Berger;
Dr E Antiono Chiocca; DrMichael Vogelbaum; ProfessorHughes
Duffau; Professor Joahn Pallud; Professor Walter Stummer; Pro-
fessor Manfred Westphal; Professor Jorg Tonn; Professor Roland
Goldbrunner; ProfessorMarkBernstein; ProfessorGelareh Zadeh;
Professor Francesco diMecco; Professor Franco Servadei; Professor
Lorenzo Bello; Professor Domenico Davella; Professor Alessandro
Olivi.
Data collection and analysis
Selection of studies
We identified studies in three stages. During title/abstract screen-
ing (for both intervention and economic analyses), we used a ma-
chine learning classifier designed to distinguish RCTs from non-
RCTs and applied this tool to de-duplicated electronic search re-
sults (Wallace 2017). This classifier assigned a probability score
to each retrieved citation (title-abstract record) that reported an
RCT. Citations with an assigned probability score greater than or
equal to 0.1 were retained; we automatically discarded citations
with a probability score less than 0.1.
Two review authors (MGH and DGB) independently examined
and screened remaining abstracts to see if they met the inclusion
or exclusion criteria. Next, we obtained the full texts of selected
studies, which we further examined and compared against the in-
clusion and exclusion criteria. At all times, we resolved disagree-
ments through discussion. If sufficient data were not available for
assessment or there was uncertainty about inclusion criteria, we
contacted the relevant trial authors for clarification.
Data extraction and management
For included studies, two review authors (MGH and DGB) in-
dependently abstracted data using a prespecified form designed to
gather information required for characteristics of included studies
and validity tables (Juni 2001). We resolved differences by discus-
sion. Specific data extracted included the following.
• Participant characteristics: age (mean and range), gender,
performance status based on Karnofsky performance score (KPS)
(Table 1) or WHO score (Table 2) (Karnofsky 1948; Oken
1982), tumour location, contrast enhancement, and tumour
histology.
• Trial characteristics: inclusion and exclusion criteria,
randomisation methods and stratification, allocation
concealment (if applicable), blinding (of whom and when), and
statistics. Definitions identified will include extent of resection,
progression, and adverse events.
• Intervention: iMRI: field strength, timing, type of scanner
(separate suite or ’double-donut’), sequences performed, contrast
administration, and reporting methods. Neuronavigation:
imaging sequences and timing, brand of equipment. 5-ALA:
dose and timing, timing of ultraviolet light used intraoperatively,
microscope used. Ultrasound: brand, timing, operator
experience. Additionally, surgical decision making influenced by
intraoperative imaging should be stated.
• Outcome assessment: extent of resection (and measurement
methods), overall survival, PFS, QoL, and adverse events. We
recorded additional quality control information on follow-up, as
well as presence of an intention-to-treat cohort, deviations from
protocol, and post-recurrence management.
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Assessment of risk of bias in included studies
We critically appraised trials deemed relevant according to the
criteria reported in NHS CRD Report No. 4 (CRD 2008). We
allocated trials according to risk of bias as described in theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We covered specific core ’Risk of bias’ items including selection,
performance, detection, attrition (deeming this to be adequate if
at least 80% of participants were assessed for all outcomes specified
in the review), reporting, and other biases. Operator blinding was
not possible, but participant and outcome assessment blinding was
desirable, although not mandatory. Two review authors (MGH
and DGB) provided independent critical appraisal. We resolved
disputes through discussion.
Measures of treatment effect
• Time-to-event data (survival and PFS): We abstracted the
log hazard ratio (HR) and standard error (SE) of the log HR for
inputting into Review Manager 5 (Review Manager 2014). We
additionally presented the overall numbers of participants
experiencing the event of interest during the trial period. If the
HR and its variance were not presented (i.e. other survival data
were presented, e.g. median survival, ranges or percentages at
stated time points), we attempted to abstract the data required to
estimate these (Parmar 1998).
• Continuous outcomes (QoL and extent of resection): We
abstracted the final value and standard deviation (SD) of the
outcome of interest for each treatment arm at the end of follow-
up.
• Dichotomous outcomes (adverse events, mortality, and
extent of resection): We abstracted the number of participants in
each treatment arm who experienced the outcome of interest to
estimate a risk ratio (RR).
• Dichotomous and continuous data: We abstracted the
number of participants assessed at each endpoint.
When possible, all data abstracted were those relevant to an in-
tention-to-treat analysis. In the case of missing data required for
review outcomes, we contacted study authors to request the per-
tinent information. Two review authors (MGH and DGB) ex-
tracted data and entered it into Review Manager 5.
Unit of analysis issues
We did not anticipate any unit of analysis issues, and there were
none to note.
Dealing with missing data
In the case of missing data required for review outcomes, we con-
tacted study authors. We did not impute missing outcome data
for any of the outcomes.
Assessment of heterogeneity
We planned to assess heterogeneity between studies by visually
inspecting forest plots, estimating the percentage of heterogeneity
(I2 statistic) between trials that could not be ascribed to sampling
variation (Higgins 2011), and performing a formal statistical test
of the significance of identified heterogeneity (Deeks 2001). How-
ever, this was not applicable as we did not conduct meta-analyses.
Assessment of reporting biases
We intended to construct funnel plots of treatment effect versus
precision to investigate the likelihood of publication bias. Had
these plots suggested that treatment effects may not have been
sampled from a symmetrical distribution, as assumed by the ran-
dom-effects model, we planned to perform additional meta-anal-
yses using the fixed-effect model.
Data synthesis
Two review authors (DGBandMGH) independently entered data
into Review Manager 5. We planned to pool data if trial charac-
teristics (methodology, participants, interventions, controls, and
outcomes) were similar. We planned to use the following meth-
ods in the Data synthesis, Subgroup analysis and investigation of
heterogeneity, and Sensitivity analysis to perform meta-analyses.
• Time-to-event data: We intended pool HR and variance
using the generic inverse variance function of Review Manager 5.
• Continuous outcomes: We intended to pool mean
differences (MDs) between treatment arms at the end of follow-
up if all trials measured the outcome on the same scale, or
otherwise use the standardised mean difference (SMD).
• Dichotomous outcomes: We intended to calculate the RR
for each study and then pool values for all studies.
We planned to use random-effects models for all meta-analyses
(DerSimonian 1986), but to perform additional fixed-effect anal-
yses if an asymmetrical distribution was found (see Assessment of
reporting biases).
We presented the overall quality of evidence for each outcome (see
Types of outcome measures) according to the GRADE approach,
which takes into account issues related not only to internal validity
(risk of bias, inconsistency, imprecision, publication bias) but also
to external validity (e.g. directness of results) (Langendam 2013).
We created a ’Summary of findings’ table based on the methods
described in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011) and using GradePro GDT. We used
the GRADE checklist and GRADE Working Group for quality
of evidence definitions (Meader 2014). We downgraded evidence
by one level for serious concerns (or two levels for very serious
concerns) for each limitation, as follows.
• High quality: We are very confident that the true effect lies
close to that of the estimate of the effect.
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• Moderate quality: We are moderately confident in the effect
estimate: the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
• Low quality: Our confidence in the effect estimate is
limited: the true effect may be substantially different from the
estimate of the effect.
• Very low quality: We have very little confidence in the effect
estimate: the true effect is likely to be substantially different from
the estimate of effect.
Subgroup analysis and investigation of heterogeneity
Owing to differences in prognosis, we planned to perform sub-
group analyses according to tumour type, including:
• high-grade glioma;
• low-grade glioma; or
• primary versus recurrent disease in high-grade glioma and
primary disease versus disease progression in low-grade glioma.
Sensitivity analysis
We planned to perform a sensitivity analysis to investigate how
trial quality affected the robustness of findings. We planned to
perform a subsequent sensitivity analysis of trials that included
objective, blinded early postoperative MRI and histology in their
assessment of extent of resection.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies.
Results of the search
The literature search revealed a total of 4109 of records: CEN-
TRAL, 927 references; MEDLINE, 519 references; Embase, 887
references. After de-duplication and use of the Cochrane RCT
classifier, 790 records remained.
We utilised the Cochrane author support tool Covidence for ti-
tle and abstract screening of the 790 records. Two review authors
(MGH and DGB) then independently examined the remaining
20 references. We excluded those studies that clearly did not meet
the inclusion criteria, and obtained full-text copies of 8 potentially
relevant references, choosing 6 trials (reported in 12 nested publi-
cations) for inclusion. Subsequently 1 trial was excluded following
correspondence with the lead author (Wu 2007), and 1 trial was
classified as on-going (Wu 2014), resulting in 4 trials for inclusion.
Any disagreements were resolved through discussion with a third
review author (AB) (Figure 1).
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Figure 1. Study flow diagram.
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We originally planned to include one study that was labelled as
an RCT but without a description of the randomisation methods
(scored as at unclear risk of selection bias) (Wu 2007). However,
subsequent email correspondence with the lead author revealed
that “randomisation methods were not strict, and that investiga-
tors were aware of allocation prior to enrolment”. We therefore
excluded this study.
Included studies
The four included studies are described in detail in Characteristics
of included studies.
In summary, we identified two trials of intraoperative MRI
(Kubben 2014; Senft 2011), one trial of fluorescence-guided
surgery (Stummer 2006), and one trial of neuronavigation (
Willems 2006).We did not find any eligible studies of ultrasound-
guided surgery. All studies included people with presumed high-
grade glioma on preoperative imaging. None of the included tri-
als included people with low-grade glioma, although one ongoing
trial includes this patient subgroup (Wu 2014).
Intraoperative MRI
Kubben 2014 recruited 14 participants from multiple centres in
Belgium and the Netherlands between 2010 and 2012. Partici-
pants had to have a supratentorial brain tumour suspected to be a
glioblastoma and an indication for gross total resection. The trial
compared surgery with iMRI versus surgery without iMRI (of
which either arm could include neuronavigation). Outcomes were
residual tumour volume, complications, quality of life (EORTC
QLQ-C30), and overall survival. The final results were initially
supposed to be an interim analysis, but ultimately the trial was
stopped early thereafter. This unplanned interim analysis was not
specified a priori, and as a consequence the sample size would not
have taken this into account even if the trial had been fully com-
pleted.The size of the trial and circumstances around its early com-
pletion are reflected in the ’Risk of bias’ assessment and GRADE
profile (see below).
Senft 2011 recruited 58 participants from a single German neuro-
surgical centre between 2007 and 2010. Participants had to have
a known or suspected glioma that was contrast enhancing and
amenable to complete resection. The trial compared surgery with
iMRI versus surgery without iMRI (of which either arm could
include neuronavigation). The primary outcome was extent of re-
section. Secondary outcomes were volume of residual tumour on
postoperative MRI, PFS at six months, duration of surgery, and
treatment-related morbidity.
Fluorescence-guided surgery
Stummer 2006 recruited 322 participants from multiple centres
in Germany between 1999 and 2004. Participants had to have a
malignant glioma on imaging. The trial compared surgery with 5-
ALA versus surgery without 5-ALA (of which either arm could in-
clude neuronavigation). Primary outcomes were complete tumour
resection on MRI (< 72 hours’ post-operation and > 1.5 T) and
PFS. Secondary outcomes were residual tumour volume, overall
survival, type and severity of neurological deficits after surgery,
and toxic effects.
Neuronavigation
Willems 2006 recruited 45 participants from a singleDutch centre
between 1999 and 2002. Participants had to have a single space-
occupying lesion. The trial compared surgery with neuronaviga-
tion versus surgery without neuronavigation. Primary outcomes
were extent of resection and survival. Secondary outcomes were
procedure duration, usefulness of neuronavigation, extent of re-
section, QoL, and postoperative course (including neurological
status and adverse events).
Excluded studies
We excluded 12 studies, as follows (see Characteristics of excluded
studies).
• Seven were not RCTs (Czyz 2011; Koc 2008; Stepp 2007;
Wu 2003; Wu 2004; Zhang 2015).
• Three were only presented as abstracts and we were unable
to obtain sufficient information even after attempting
correspondence with the original trial authors (Chen 2011;
Chen 2012; Seddighi 2016).
• Three did not directly compare an intraoperative imaging
intervention with either another intraoperative imaging
intervention or standard surgery (Eljamel 2008; Rohde 2011;
Stummer 2017).
Risk of bias in included studies
Summary data for risk of bias are presented in table format (Figure
2; Figure 3). A detailed description is provided below and in the
Characteristics of included studies.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Randomisation methods
Randomisation methods were described and were satisfactory in
all four included trials, for a judgement of low risk of bias (Kubben
2014; Senft 2011; Stummer 2006; Willems 2006).
Allocation concealment
We assessed one trial in which allocation concealment was poten-
tially inadequate (i.e. sealed envelopes) and judged to be at high
risk of bias (Senft 2011), one trial as at low risk of bias (Stummer
2006), and the remaining two trials as at unclear risk of bias
(Kubben 2014; Willems 2006).
Blinding
Blinded assessment for extent of resection was performed in three
trials (Kubben 2014; Senft 2011; Stummer 2006), and for histo-
logical assessment in one trial (Stummer 2006). Regarding overall
survival, blinding would not affect outcome reporting but could
affect subsequent treatment. For QoL, PFS, and adverse events,
blinding would likely affect the outcomes reported. All trials were
not blinded to participants or clinicians.
Incomplete outcome data
In one trial all participants were accounted for (Kubben 2014).
In two trials all participants were accounted for, but an inten-
tion-to-treat analysis was not performed, as those participants that
had alternative pathological diagnoses were excluded (Senft 2011;
Stummer 2006). In the remaining trial there was evidence of at-
trition bias for extent of resection (analysis of 32 out of 42 partic-
ipants) (Willems 2006).
Selective reporting
One trial reported all outcomes and was therefore at low risk of
reporting bias (Senft 2011). Selective outcome reporting was ap-
parent in three trials: one trial did not report quality of life out-
comes (Kubben 2014); one trial did not report full outcome data
in the form of figures and appropriate statistics for survival, PFS,
and adverse events for 5-ALA (Stummer 2006); and one trial did
not present full data for survival, QoL, or adverse events (Willems
2006). Adverse event data in all studies were particularly poorly
reported in terms of total number of events, number of partici-
pants with multiple events, and timing of events.
Other potential sources of bias
One of the issues with iMRI is attribution bias. Because a surgeon
knows he can check for residual disease, he does not operate as
aggressively as he might if he could not check for residual disease
during the operation. So when a scan is done residual disease is
more likely to be detected, removed, and the success of the removal
attributed to the iMRI. This is likely to affect outcomes that report
a difference between the first intraoperative and final postoperative
MRI scans.
Early cessation of trial
All four trials were stopped early based on the results of interim
analyses. Kubben 2014 was stopped early based on the results of
an interim analysis not specified a priori. Given the low number
of participants involved, we excluded this trial from quantitative
analysis. Senft 2011 was stopped early based on the results of an
interim analysis not specified a priori. Significance values were
consequently adjusted (a P value of less than 0.04was subsequently
regarded as significant). Stummer 2006 was stopped early based
on the results of a scheduled interim analysis with compensated
power calculation. Willems 2006 was stopped early but no reason
was given.
Industry sponsorship
Industry sponsorship was apparent in three trials. Kubben 2014
was financially supported byMedtronic Navigation, but the spon-
sors “were not involved in writing the protocol, had no access to
the data, was not involved in writing the manuscript, and had no
veto right for submission.” Senft 2011 included authors that had
received an honorarium from Medtronic (who manufactured the
iMRI machine used in the study), although it was emphasised that
the study receivedno funding fromMedtronic. Stummer 2006was
sponsored by medac GmbH (who manufacture Gliolan), which
was involved in the study design, quality assurance, and quality
control but had no role in the interpretation of data, and the cor-
responding author had final responsibility for the article (although
the author was a paid consultant to both medac GmbH and Zeiss,
which manufactures the microscopes used for 5-ALA). One trial
did not state if there were conflicts of interest (Willems 2006).
Effects of interventions
See: Summary of findings for the main comparison iMRI
image-guided surgery compared to standard surgery for high-grade
glioma; Summary of findings 2 5-ALA image-guided surgery
compared to standard surgery for high-grade glioma; Summary
of findings 3 Neuronavigation image-guided surgery compared
to standard surgery for high-grade glioma
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Extent of resection
Meta-analysis was not appropriate due to differences in the tu-
mours included (eloquent versus non-eloquent locations) and vari-
ations in the image guidance tools used in the control arms (usually
selected utilisation of neuronavigation). Due to the small num-
ber of studies (four), we did not construct a funnel plot. The risk
ratio (RR) for the extent of resection in participants with high-
grade glioma favoured the experimental arms in two of the four
trials reporting this outcome, indicating a lower risk of having an
incomplete resection with the intervention.
• iMRI was assessed in two trials (Kubben 2014; Senft 2011).
• 5-ALA was assessed in the trial of Stummer 2006.
• Neuronavigation was assessed in the trial of Willems 2006.
Complete resection
• iMRI: In the trial of Senft 2011, complete tumour
resection was achieved in 23/24 (96%) of participants in the
intervention group compared with 17/25 (68%) of participants
in the control group (RR for incomplete resection 0.13, 95%
confidence interval (CI) 0.02 to 0.96; very low-quality evidence).
In the Kubben 2014 trial, tumour resection was reported using
residual tumour volume and data for complete tumour resections
were not available.
• 5-ALA: Complete resection was performed in 90/139
(65%) of participants in the intervention group versus 47/131
(36%) of participants in the control group (RR for incomplete
resection 0.55, 95% CI 0.42 to 0.71; low-quality evidence).
• Neuronavigation: Complete resection was achieved in
three participants in the control group and five participants in
the neuronavigation group. However, there was significant
attrition, with not all participants having complete imaging, and
the denominators for these figures were not stated, precluding
meta-analysis (very low-quality evidence).
Adverse events
Adverse events (AEs) were reported in an inconsistent manner be-
tween trials and not according to the prespecifiedmanner required
in our protocol. Specifically, datawere not available for participants
at risk, participants with multiple events, timing of events, and
outcomes of events. We therefore adopted a descriptive method
using the data available to describe the AEs in each trial.
• iMRI: In the trial of Senft 2011, new or aggravated
neurological deficits were present in 2/25 (8%) of participants in
the control group and 3/24 (13%) participants in the iMRI
group; intraoperative imaging did not lead to continuation of
tumour resection in any of the participants with AEs. Two
participants had symptomatic haematomas, which were not
attributable to the use of iMRI. In one participant, hemianopia
was deliberately accepted due to tumour extension around the
temporal horn of the lateral ventricle involving the optic
radiation. In the Kubben 2014 trial, a single participant in the
intervention arm experienced a postoperative haemorrhage.
• 5-ALA: Adverse events were present in 58.7% of the
intervention arm versus 57.8% of the control arm. Neurological
AEs were present in 42.8% of the intervention arm (7.0% grade
3 to 4) and 44.5% of the control arm (5.2% grade 3 to 4).
Significant neurological AEs were present in 12.4% of the
intervention arm versus 11.6% of the control arm. The number
of participants with a deterioration in the National Institutes of
Health Stroke Scale compared to baseline tended to be higher in
the intervention arm at 48 hours (26.2% with 5-ALA versus
14.5% in the control arm) but not at 7 days (20.5% versus
10.7%), 6 weeks (17.1% versus 11.3%), and 3 months (19.6%
versus 18.6%). No denominators were given for each result,
preventing calculation of the RR and CI.
• Neuronavigation: New or worsened neurological deficits
were present at three months in 45.5% of participants in the
control group and 18.2% of participants in the neuronavigation
group. During the first three months after surgery, seven
participants (31.8%) in the control group and seven (30.4%) in
the neuronavigation group experienced a new, non-neurological
adverse event. In three participants in the neuronavigation
group, these events were fatal (pulmonary embolism, cardiac
arrest with pulseless electrical activity, and postoperative
pulmonary insufficiency). Other adverse events included
pulmonary or urinary tract infection, surgical removal of an
epidural haematoma, surgical cyst drainage, repeated tumour
debulking, cerebrospinal fluid leakage, postoperative delirium,
and insufficiently treated steroid-induced diabetes.
Survival
• iMRI: Senft 2011 did not assess this outcome, while
Kubben 2014 did not report overall survival in the prespecified
manner for inclusion.
• 5-ALA: There was no difference in overall survival between
the intervention and control arms (hazard ratio (HR) 0.82, 95%
CI 0.62 to 1.07). Median survival was also reported and this was
15.2 months (95% CI 12.9 to 17.5) in the intervention arm
versus 13.5 months (95% CI 12.0 to 14.7) in the control arm.
• Neuronavigation: The median survival time was 9 months
in the control arm and 5.6 months in the intervention arm and
the HR was reported to be 1.6. However, no confidence intervals
were available or able to be calculated.
Time to progression or progression-free survival
• iMRI: In Senft 2011, the median PFS in the intervention
arm was 226 days (95% CI 0.0 to 454) versus 154 days (95% CI
60 to 248) in the control arm. HRs or their respective CIs were
not available and could not be calculated. Kubben 2014 did not
assess these outcomes.
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• 5-ALA: Median PFS was 5.1 months (95% CI 3.4 to 6.0)
in the intervention arm versus 3.6 months (95% CI 3.2 to 4.4
months) in the control arm. HRs and their respective CIs were
not available and could not be calculated.
• Neuronavigation: These outcomes were not assessed.
Quality of life
• iMRI: Senft 2011 and Kubben 2014 did not report data for
this outcome.
• 5-ALA: This outcome was not assessed.
• Neuronavigation: Quality of life questionnaires at 3
months’ postoperatively were completed by 19 participants
(eight in the neuronavigation arm and 11 in the standard surgery
arm), constituting 64.5% of all eligible participants. The
questionnaire included one part with 30 general questions and
another part with 20 brain-specific questions (BN-20). Out of
26 outcome measures that were presented, the direction of
change differed in seven (all in the BN-20 group): four were in
favour of the neuronavigation group and three were in favour of
standard surgery. No statistical analysis was presented.
We considered this evidence to be of low to very low quality
for all reported outcomes (Summary of findings for the main
comparison; Summary of findings 2; Summary of findings 3).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
5-ALA image-guided surgery compared to standard surgery for high-grade glioma
Patient or population: high-grade glioma
Settings: specialist centres
Intervention: 5-ALA image-guided surgery (based on post-operat ive MRI)
Comparison: standard surgery
Outcomes Illustrative comparative risk* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Image-guided surgery
Extent of resection:
complete resection
641 per 100 35 per 100
(27 to 45)
RR 0.55 (0.42 to 0.71) 270 part icipants
(1 study)
⊕⊕©©2
low
Highly selected part ic-
ipants with potent ial
bias in allocat ion and
performance
Adverse events Inadequately and inconsistent ly reported in the trial ⊕©©©3
very low
Adverse events were re-
ported in an inconsis-
tent manner and not ac-
cording to the manner
prespecif ied in our pro-
tocol. Addit ionally, we
were mainly interested
in ident if ying serious
adverse events, which
were inadequately re-
ported
Overall survival Not est imable due to report ing of HR and since
just a single trial reported on this outcome we did
not arbitrarily choose a snap shot in t ime in which
to use as basis to calculate the assumed and
corresponding risks as this may be misleading
HR 0.82
(0.62 to 1.07)
270 part icipants
(1 study)
⊕⊕©©2
low
The overall quality of
this outcome was low in
this trial and was down-
graded for highly se-
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lected part icipants with
potent ial bias in alloca-
t ion and performance
Progression- free sur-
vival
Not adequately reported in the trials ⊕©©©3
very low
Progression-f ree sur-
vival or t ime to pro-
gression was not ade-
quately reported in the
trial
Quality of life Inadequately reported or not assessed at all in the included trials ⊕©©©3
very low
Quality of lif e was not
reported in the trial
* The basis for the assumed risk is only based on individual trials as only single trial reports were available. The corresponding risk (and its 95% conf idence interval) is based
on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
5-ALA: 5-aminolevulinic acid; CI: conf idence interval; HR: hazard rat io; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Expressed in terms of risk of incomplete resect ion (bad outcome).
2Highly selected part icipants with potent ial bias in allocat ion and performance as well as in other ’Risk of bias’ domains, thus
downgraded by two levels.
3Outcome was not reported (or inadequately reported for meaningful conclusions to be drawn), therefore giving lowest quality
of evidence judgement.
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Neuronavigation image-guided surgery compared to standard surgery for high-grade glioma
Patient or population: high-grade glioma
Settings: specialist centres
Intervention: neuronavigat ion image-guided surgery (based on post-operat ive MRI)
Comparison: standard surgery
Outcomes Illustrative comparative risk* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Image-guided surgery
Extent of resection:
complete resection
Not est imable Not est imable Not reported 45 part icipants
(1 study)
⊕©©©1,2,4
very low
Small study of highly
selected part icipants at
very high risk of alloca-
t ion bias.Complete re-
sect ion was achieved
in three part icipants
in the control group
and f ive part icipants
in the neuronavigat ion
group. However, there
was signif icant attri-
t ion, with not all part ici-
pants complet ing imag-
ing, and the denomina-
tors for these f igures
were not stated, pre-
cluding formal analysis
Adverse events Inadequately and inconsistent ly reported in the trial ⊕©©©2
very low
Adverse events were re-
ported in an inconsis-
tent manner and not ac-
cording to the manner
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prespecif ied in our pro-
tocol. Addit ionally, we
were mainly interested
in ident if ying serious
adverse events, which
were inadequately re-
ported
Overall survival Not est imable ⊕©©©3
very low
Not reported by trial au-
thors so graded as very
low quality evidence
Progression- free sur-
vival
Not est imable ⊕©©©2
very low
Progression-f ree sur-
vival or t ime to progres-
sion was not reported
in the trial
Quality of life Inadequately reported or not assessed at all in the included trials ⊕©©©3
very low
Quality of lif e was re-
ported in the trial but
only 19 part icipants
(8 in the neuronaviga-
t ion arm and 11 in
the standard surgery
arm) completed ques-
t ionnaires postopera-
t ively at 3 months’, con-
st itut ing only 64.5% of
all eligible part icipants,
and no stat ist ical anal-
ysis was presented
* The basis for the assumed risk is only based on individual trials as only single trial reports were available. The corresponding risk (and its 95% conf idence interval) is based
on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Small t rial so quality of the evidence downgraded by one level.
2Highly selected part icipants with potent ial bias in allocat ion and performance as well as in other ’Risk of bias’ domains, thus
downgraded by two levels.
3Outcome was not reported (or inadequately reported for meaningful conclusions to be drawn), therefore giving lowest quality
of evidence judgement.
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D I S C U S S I O N
Summary of main results
We identified two RCTs for iMRI (Kubben 2014; Senft 2011),
one for fluorescent-guided surgery with 5-ALA (Stummer 2006),
and one assessing neuronavigation using standard preoperative
MRI sequences (Willems 2006). Formal meta-analysis was not
possible due to the different comparisons and variability in the
control arm population between trials. We were therefore limited
to performing a narrative analysis of the included trials.
Two trials demonstrated a benefit for intraoperative imaging tech-
nology (iMRI and 5-ALA, respectively) in terms of extent of resec-
tion (the primary outcome) (Senft 2011; Stummer 2006). Overall
survival data were available for 5-ALA only; there was no clear
evidence that 5-ALA improved overall survival. Data for PFS were
only available for two trials, and were not available in the format
specified (hazard ratios and their variance). Nevertheless, there
was a suggestion that 5-ALA increased PFS compared with stan-
dard surgery. Quality of life data were only reported in a single
trial, and there was significant attrition and reporting bias. Adverse
event reporting varied considerably between trials but in general
was poorly performed. With 5-ALA, it appears that neurological
deterioration is more common after fluorescence-guided surgery.
The studies that reported on this effect noted that it occurred
mainly among those with fixed deficits and early after surgery, but
there was subsequently a trend towards recovery (Stummer 2006).
Other adverse events appeared to be rare and similar in frequency
between study arms.
To supplement the main systematic review of effects, we sought to
identify cost analyses and economic evaluations that compared the
interventions with each other or between different variants of the
same intervention. A search of MEDLINE and Embase identified
six such studies (Eljamel 2016; Esteves 2015; Hall 2003; Kowalik
2000; Makary 2011; Schulder 2003; Slof 2015) (one study was
reported in two papers - Hall 2003; Kowalik 2000).
Of the six studies, three studies compared iMRI to conventional
surgery (Kowalik 2000; Makary 2011; Schulder 2003); two com-
pared 5-ALA with white light surgery (Esteves 2015; Slof 2015);
and one compared conventional, 5-ALA, fluorescein, ultrasound,
and iMRI surgery (Eljamel 2016). Three studies were conducted
in the USA (Kowalik 2000; Makary 2011; Schulder 2003), one in
Portugal (Esteves 2015), and one in Spain (Slof 2015), and for one
it was unclear (but was probably the USA) (Eljamel 2016). Four
studies were based on non-randomised retrospective comparative
cohorts (Kowalik 2000;Makary 2011; Schulder 2003; Slof 2015);
one was based on a review and pairwise meta-analyses (Eljamel
2016), and one used data from a trial and retrospective cohorts
(Esteves 2015). The cohort studies all involved fewer than 100
participants, except for the study by Slof 2015, which included
254 participants who received 5-ALA and 120 who received white
light surgery. All the studies except one (Esteves 2015), which in-
tegrated data using a Markov model, were based on comparisons
of individual patient level data.
In terms of costs, what costs were included and over what time
horizon varied markedly. Only one study considered costs over
the patient lifetime (Esteves 2015), and one only considered the
drug cost (Slof 2015). The other studies considered costs incurred
in hospital for the index surgery. Costs were reported in US dol-
lars in four studies (Esteves 2015; Kowalik 2000; Makary 2011;
Schulder 2003), but the price year (2005/6) was stated only in
one study (Makary 2011). The other two studies reported costs in
Euros, and the price year was 2012 in one study, Esteves 2015, and
not stated in the other (Slof 2015). Two studies were cost anal-
yses only (Kowalik 2000; Schulder 2003). Effects were resection
rates (Eljamel 2016), resection-free years (Makary 2011), quality-
adjusted life years (Eljamel 2016; Esteves 2015; Slof 2015) PFS
(Esteves 2015), and life years (Esteves 2015).
For the comparison of iMRI with conventional surgery, two stud-
ies reported a potential cost saving driven by reductions in length
of stay (Kowalik 2000; Schulder 2003), and third study reported
lower mean costs that were not statistically significant (Makary
2011). The one cost-effectiveness analysis reported a longer in-
terval to resection (20.1 versus 6.7 months; P = 0.02); further re-
sults suggested iMRI was more cost-effective in terms of cost per
resection-free years. Another study reported that iMRI was the
most costly of conventional, 5-ALA, fluorescein, and ultrasound-
assisted surgery (Eljamel 2016). iMRI was the least cost-effective,
but the results could not be replicated from the data presented in
the study. Estimates of cost-effectiveness (and cost over a longer
follow-up) need to considered in the light of the very limited evi-
dence for iMRI where there is a benefit shown in terms of extent
of resection but no evidence in the review of clinical effectiveness
on overall survival.
For the comparison of 5-ALA and standard surgery, 5-ALA was on
average more costly in both studies, but results in more quality-
adjusted life years over the patient lifetime or over the time to
progression of disease (Esteves 2015; Slof 2015). In both cases
the study authors concluded that the extra costs were worth the
extra quality-adjusted life years and that these conclusions were
consistent over all sensitivity analyses conducted. These findings
of extra effectiveness in the economic studies need to be considered
in context of the findings of the review of the best available clinical
effectiveness data summarised above. National Institute forHealth
and Care Excellence (NICE) guidance on the cost-effectiveness of
5-ALA is expected to be published in June 2018.
Overall completeness and applicability of
evidence
All the identified trials included highly selected participants in
specialised centres, and the applicability of these findings to amore
general population needs to be carefully considered. Participants
included int he trials tended to be generally young and of good
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performance status. In addition, most trials also clearly specified
the types of tumours that were to be included, and would not
have randomised those patients with eloquent tumours or where
a complete resection was not feasible. Potentially those enrolled
in one of the iMRI trials (Senft 2011) were likely to have more
resectable or less eloquent tumours than those in the 5-ALA trial
(Stummer 2006), given the far higher resection rates in both arms
of the iMRI study (96% iMRI and 68% control versus 65% 5-
ALA and 36% control).
The majority of included trials only enrolled participants with
probable high-grade glioma. We identified no RCTs for ultra-
sound-guided surgery, whichmay reflect the less widespread appli-
cation of this particular technology. There are theoretical advan-
tages to this technology, such as relative affordability, repeatabil-
ity, and possibly better sensitivity in low-grade tumours than the
other included intraoperative imaging modalities. Nevertheless, it
currently does not have the same evidence base as other intraoper-
ative imaging modalities to recommend its use in routine clinical
practice.
Quality of the evidence
It is clearly feasible to performRCTs for new surgical interventions,
and it appears now to have become standard practice to perform
an RCT for assessing new intraoperative imaging technologies.
The openness of major centres to enrolling participants in RCTs
to provide clear outcome data is a major step forward in neuro-on-
cology. Some aspects of the included trials were at low risk of bias,
such as randomisation methods and blinded, objective reporting
for extent of resection. However, the overall the risk of bias was
high, and there were consistent concerns with stopping trials early
and the role of industry involvement (Summary of findings for the
main comparison; Summary of findings 2; Summary of findings
3).
Extent of resection was the primary outcome for all of the in-
cluded trials. This has the advantage of being the outcome most
directly influenced by intraoperative imaging. However, there is
still no evidence from RCTs that resection (either total or less
than total) improves outcomes for high-grade glioma over biopsy
alone (Hart 2011). Subgroup analyses, particularly for the 5-ALA
trial (Stummer 2006), have shown that those participants that
have a complete resection of all contrast-enhancing tumour sur-
vive longer than those with residual tumour (Pichlmeier 2008).
Studies of chemotherapy have also found that those without resid-
ual tumour survive longer (Stupp 2005). While this is not direct
evidence in favour of complete resection, but rather a post hoc
non-randomised subgroup analysis, it is becoming increasingly ap-
parent that a complete tumour resection is desirable, particularly
when it can be achieved safely. Precisely how much a complete
resection contributes towards the overall outcome is unclear. New
methods of imaging (e.g. amino acid positron emission tomog-
raphy) have found that tumours frequently extend out from the
contrast-enhancing margin on MRI (Miwa 2004). However, vali-
dation of this approach has yet to be established, and the need for
a cyclotron makes widespread application and testing a challenge
in the UK, therefore MRI in assessing residual tumour remains
the current standard of care.
After extent of resection, studies tended to focus on PFS rather
than overall survival. There are certain advantages to this in that
possibly fewer participants are required and the results may be
available sooner. Additionally, it may provide a more direct assess-
ment of the effect of the primary intervention that is not con-
founded by subsequent therapy. However, it can be argued that
overall survival should still remain the main outcome of interest.
Firstly, survival is so short in high-grade glioma that the practical
benefits of assessing PFS are less relevant. Secondly, assessment of
PFS can be more subjective, and is critically dependent on the
timing and interpretation of imaging, which can often be compli-
cated (Wen 2010).
Quality control for surgical neuro-oncology trials is an emerging
area (GNOSIS 2007). Standardisation of reporting is required to
allow clear comparisons between trials in meta-analyses. Detailed
reporting is required for tumour location with regard to eloquent
brain; operative technique used; postoperative imaging protocol;
assessment of extent of resection; and recording of adverse events
(including total numbers of events, total number of participants at
risk, number of participants with multiple events; severity, timing,
andoutcome of events, i.e. resolutionor persistence of neurological
deficits).
Potential biases in the review process
We took multiple steps in the review process to minimise bias,
including double independent literature sift and data extraction,
not pooling results due to heterogeneity, and using strict inclusion
criteria. Overall, these steps acted to minimise bias and restrict the
review to the best available evidence. Notably this led to one trial
that was titled as an RCT and included in an earlier version of
this review being excluded. Specificially, the lead author stated that
randomisation was not strict, surgeons were aware of allocations
prior to enrolment, and that bias of participant allocation was
inevitable. In a previous Cochrane Review (Barone 2014), this
study was included to allow open discussion of its methodology,
while for this review we felt it more appropriate to concentrate on
the highest-quality evidence in order to generate the most robust
findings.
Notably, the majority of trials identified through the search strat-
egy were not RCTs. It could be argued that excluding this volume
of data biases our review and that it would be more appropriate to
consider a Cochrane Review of non-randomised studies (NRS).
However, the issue of selection bias is critical, particularly in sur-
gical trials. Participants enrolled in a NRS are likely to have a bet-
ter prognosis than a control population, and it is impossible to
accurately account for this bias without using randomisation. It
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would therefore not be clear what benefit intraoperative imaging
had on the overall outcome. Meta-analysis of RCTs remains the
most reliable way of assessing the benefits of specific intraoperative
imaging modalities. However, NRS may also have a role, particu-
larly regarding technology development and reporting of adverse
events.
This review included two specific groups of technologies, those
that used imaging obtained intraoperatively and those that used
imaging obtained preoperatively for use in an intraoperative man-
ner. We felt that both methods were suitable for comparison, as
the goals are similar: namely, to achieve maximal safe resection via
the application of surgical technology. A major concern with pre-
operative imaging is intraoperative brain shift, whereby anatom-
ical localisation is affected by events that occur during surgery
(e.g. anaesthesia, brain retraction, tumour resection, dural open-
ing, and cerebrospinal fluid drainage). Imaging obtained intraop-
eratively can theoretically account for brain shift and allow more
accurate navigation than imaging obtained preoperatively. In this
review we found that a single trial did not demonstrate an effect
for intraoperative imaging utilising preoperatively acquired data
(Willems 2006).
Another technique that is commonly used in neuro-oncology
surgery is awake craniotomy. This is often perceived as a technol-
ogy to make surgery safer by allowing intraoperative mapping of
eloquent brain. It is not typically regarded as a technique to max-
imise extent of resection and was therefore not included in this
review.
We did not subject these studies to critical appraisal, and we do
not attempt to draw any firm or general conclusions regarding the
relative costs or efficiency of the interventions being compared. For
the comparison of iMRI surgery with conventional surgery, it is
clear that the available economic evidence is, at best, equivocal. For
the comparison of 5-ALA with white light surgery, the available
economic evidence indicates that, from an economic perspective,
use of 5-ALA could be a promising strategy but effectiveness data
used in the economic studies is not consistent with the findings of
the review of effectiveness.
Agreements and disagreements with other
studies or reviews
We are not aware of any other similar reviews that compare all the
different types of intraoperative imaging or other interventions
to maximise the extent of resection in neuro-oncology. Currently,
there are no national guidelines appraising the use of any of the
technologies, for example by NICE, but guidance on 5-ALA and
iMRI is expected in 2018 when the NICE guidelines for the man-
agement of primary brain tumours are published. Many of the tri-
als are relatively recent and appraisal is often limited to a linked ed-
itorial. In addition, many of the techniques have only been used in
specialised trial centres, and real-world experience is limited. Fur-
ther prospective data reporting such real-world experience would
help inform future clinical guidelines and NHS (National Health
Service) policy by reporting data on patients who are unsuitable
for RCTs, for example due to co-morbidities.
An interim analysis of an on-going trial of iMRI is broadly in agree-
ment with the findings of this review (Wu 2014). This reported
outcomes on 114 out of a projected 304 participants. Complete
resection was achieved in 86% of the iMRI arm versus 53% of the
control arm. There was no difference in AEs or PFS while OS was
not reported.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Intra-operative imaging technologies, specifically iMRI and 5-
ALA, may be of benefit in maximising extent of resection in par-
ticipants with high grade glioma. However, this is based on low
to very low quality evidence, and is therefore very uncertain. The
short- and long-term neurological effects are uncertain.
The purpose of these technologies is to make surgical resection
safer and more effective. Patient selection, patient-specific infor-
mation, and informed consent are all essential to ensure that these
technologies are used appropriately in the pathway of care. Stan-
dardisation of patient management through the use of evidence-
based clinical practice will ensure consistent surgical standards of
care wherever a patient is treated.
Patient selection must be emphasised. All the trials included pre-
dominantly young participants of good performance status and
with a well-defined tumour in a non-eloquent region that was
amenable to safe complete resection.
Implications for research
The current studies provide a limited knowledge base upon which
to consider implementing such technologies. Important questions
remain about benefit in terms of overall survival, progression-free
survival, and the risk of adverse events. Future trials could be done
with a similar design to those already performed but with simple
improvements to the trial methodology and outcome reporting.
A direct comparison between individual intraoperative imaging
technologies could be of benefit to compare their relative merits
and in particular help to provide cost-effectiveness data. The most
logical comparison would be between iMRI and 5-ALA, while ul-
trasound and advanced imaging neuronavigation (e.g. tractogra-
phy of functional imaging based) have theoretical advantages but
currently have not been the subject of a randomised controlled trial
(RCT). However, units with access to all technologies are likely to
be rare, and patients who are suitable for either procedure are likely
to be very highly selected, although experience-based RCTs are a
possible way around this. Nevertheless, there are ongoing RCTs
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comparing different forms of image-guided surgery, and these can
hopefully be incorporated into an update of this review once they
are completed (Ongoing studies). A network meta-analysis may
allow indirect comparisons of each technology, and a formal eco-
nomic analysis could allow financial factors to be facilitated into
the equation.
Evidence regarding extent of resection and the means with which
to achieve this is becoming stronger, but this still needs to be
balancedwithmaking surgery safer. Awake craniotomy is probably
the main means of enabling a maximal safe resection, particularly
with tumours in eloquent areas. A comparison of tractography
or functional MRI guided surgery versus awake craniotomy is
potentially a relevant question for resection of tumours in eloquent
areas.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Kubben 2014
Methods Randomised controlled trial.
Randomisation:
Participants were randomised and allocated to either conventional neurosurgery or iMRI.
Randomisation was performed by the first author using specific software for randomi-
sation in clinical trials. No randomisation blocks were used
Sample size:
“To reduce the chance for type I errors (false positive) we used an alpha value of 0.
05. To reduce the chance for type II errors (false negative) we used a beta value of 0.2
leading to a power of 0.8. We considered a 10% additional resection of the preoperative
tumor volume as the minimal clinically relevant difference, with an estimated standard
deviation of approximately 12%. This led to 23 patients in each treatment group. To
compensate for loss to follow-up we intended to include a total of 54 patients for the
complete study.”
Blinding:
“The neurosurgeon could not be blinded for the procedure. We did not intend to
blind the physicians on the ward, nor the patients. Volumetric assessment of pre- and
postoperative tumor volume was performed by a single blinded researcher.”
Participants Inclusion criteria:
Supratentorial brain tumour suspected to be glioblastoma on contrast-enhanced diag-
nostic MRI, indication for gross total resection of the tumour, age 18 years or older,
WHO Performance Scale 2 or better, ASA class 3 or better, adequate knowledge of the
Dutch or French language, and informed consent
Exclusion criteria:
Recurrent brain tumour, multiple brain tumour localisations, earlier skull radiotherapy,
earlier chemotherapy for glioblastoma, chronic kidney disease or other renal function
disorder, and a known magnetic resonance-contrast allergy
Interventions Intervention:
Low field intraoperative MRI (Medtronic PoleStar N20 0.15 Tesla moveable magnet
and the StarShield tent)
Control:
Neuronavigation guided tumour resection.
Outcomes Residual tumour volume; complications; quality of life (EORTC QLQ-C30); overall
survival
Notes Sponsored by Medtronic:
“This study is part of the PhD thesis of the first author, and has been financially sup-
ported byMedtronic Navigation. Medtronic Navigation was not involved in writing the
protocol, had no access to the data, was not involved in writing the manuscript, and had
no veto right for submission.”
Definitions:
Residual tumour volume (RTV) percentage is used as the primary endpoint to assess
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Kubben 2014 (Continued)
extent of tumour resection. Pre- and postoperative tumour volume was calculated by
segmenting the hyperintense area on contrast-enhanced T1 MRI (including enclosed
central necrosis) and subtracting the hyperintense area on native T1MRI to compensate
for blood in the resection cavity. Measurements were performed using OsiriX software
(Pixmeo SARL, Bernex, Switzerland) on Mac OS X using a Wacom Bamboo pen mouse
for contour drawing. Postoperative tumour volume was divided by preoperative tumour
volume to calculate the fraction of RTV. Multiplying the fraction with 100% provided
the RTV. In formula:
RTV = (postoperative contrast enhancement/preoperative contrast enhancement) ×
100%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed by the first
author using TEN-ALEA software for ran-
domisation in clinical trials
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “The neurosurgeon could not be blinded
for the procedure. We did not intend to
blind the physicians on the ward, nor
the patients. Volumetric assessment of pre-
and postoperative tumor volume was per-
formed by a single blinded researcher.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The neurosurgeon could not be blinded
for the procedure. We did not intend to
blind the physicians on the ward, nor
the patients. Volumetric assessment of pre-
and postoperative tumor volume was per-
formed by a single blinded researcher.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants are accounted for and in-
cluded in the analysis
Selective reporting (reporting bias) High risk Quality of life data not reported: “After
consultation of a health-technology assess-
ment expert we decided to refrain from any
further statistical analyses due to the small
sample size.”
Other bias High risk 1. Interim analysis/abbreviated study.
Stopped on the basis of the interim anal-
ysis, although this was not specified a pri-
ori. Reasons for stopping included slow re-
cruitment, technical issues with the equip-
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Kubben 2014 (Continued)
ment, prolonged duration of surgery, and
concerns over effect size (“the main reason
was that we estimated that our minimally
required difference of 10% would not be
consistent with the actual results”)
2. Industry sponsorship: “This study is part
of the PhD thesis of the first author, and has
been financially supported by Medtronic
Navigation. Medtronic Navigation was not
involved in writing the protocol, had no ac-
cess to the data, was not involved in writing
the manuscript, and had no veto right for
submission.”
Senft 2011
Methods Randomised controlled trial.
Randomisation of participants was done in blocks of 4 on a 1-to-1 ratio using BiAS for
Windows 9.01 by an assistant who had no clinical involvement in the trial
Sample size:
The sample size calculation was done to detect a difference of 25% between groups for
the primary endpoint with a power of 80%
Blinding:
Investigators who assessed eligibility of participants and scheduled surgeries were masked
to treatment group assignment by use of a sealed envelope design. Surgeons and par-
ticipants were not masked to the treatment group assignment, but the neuroradiologist
who analysed MRI data was masked
Participants Inclusion criteria:
Adults ( ≥ 18 years) with known or suspected gliomas showing distinct contrast en-
hancement on T1- weighted MRI amenable to radiologically complete resection were
eligible
Exclusion criteria:
Presence of cardiopulmonary or hepatorenal comorbidities; tumours that crossed the
midline or were located in the basal ganglia, cerebellum, brain stem, or otherwise in close
proximity to eloquent brain structures prohibiting or questioning complete resectability;
contraindications to MRI examination (e.g. pacemaker); and inability to give consent
due to neuropsychological deficits or a language barrier
Interventions Intervention:
Mobile intraoperative ultralow field (0.15 Tesla) MRI system (PoleStar N-20, Odin
Medical Technologies, Yokneam, Israel and Medtronic, Louisville, CO, USA)
Control:
“Conventional micro neurosurgical resection” including Cavitron Ultrasonic Aspirator
(CUSA) and neuronavigation. The use of intraoperative ultrasound or fluorescence-
guided surgery with 5-aminolevulinic acid was not allowed in either group
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Outcomes Primary:
Extent of resection.
Secondary:
“Volume of residual tumour on postoperative MRI and progression-free survival (PFS)
at 6 months. We also compared the duration of surgery and treatment-related morbidity.
”
Notes Definitions:
All participants underwent high-field MRI at 1.5 T or 3.0 T with and without contrast
agent within 7 days before surgery and within 72 h after surgery. 1masked, independent,
and experienced neuroradiologist (AB) assessed MRIs to establish the extent of resection
and undertake volumetric analyses of the tumours and tumour residues. Residual tumour
was defined as detectable contrast enhancement on T1-weighted imaging with a volume
of more than 0.175 cm3 on postoperative MRI as done previously.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation of participants was done in
blocks of 4 on a 1-to-1 ratio using BiAS for
Windows 9.01 by an assistant who had no
clinical involvement in the trial
Allocation concealment (selection bias) High risk Sealed envelope design
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Surgeons and participants were not
blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Only the neuroradiologist analysing the
MRI data was blinded, which is important
for assessing extent of resection. Assessors of
clinical outcomes were not masked, which
would have affected PFS and treatment-re-
lated morbidity
Incomplete outcome data (attrition bias)
All outcomes
High risk 49 of 58 participants analysed (4 excluded
in each armdue to diagnosis of ametastasis,
and 1 in the iMRI arm withdrew consent)
Selective reporting (reporting bias) Low risk All prespecified outcomes reported (extent
of resection, residual tumour volume, PFS,
and treatment-related morbidity)
Other bias High risk 1. Interim analysis/abbreviated
trial. Stopped early due to an interim anal-
ysis resulting in a reduced sample size from
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80 to 58. Due to the possible effect of this
adjustment on the alpha error and to avoid
over-interpretation of the data, a P value
of less than 0.04 was considered significant
for the primary endpoint
2. Industry sponsorship. No external fund-
ing source for the study declared, but one of
the authors received an honorarium from
Medtronic, which manufactures the scan-
ner used
Stummer 2006
Methods Randomised controlled trial.
Randomisation was done by use of a dynamic allocation algorithm at a separate research
unit, in which participants were allocated to minimise the imbalance between treatment
groups. No permuted block randomisation was applied. Treatment allocation was com-
municated to local investigators first by telephone and additionally by fax
Sample size:
Initial power calculations estimated 350 participants were required for an 80% power,
but to allow premature study termination an interim analysis was scheduled after 270
participants whereby a 20\5 difference in PFS could be identified with a power of 80%
Participants Inclusion criteria:
People aged 18 to 72 years with suspected (as assessed by study surgeon) newly diagnosed
and untreated malignant glioma. Tumours were to have a distinct ring-like pattern of
contrast enhancement with thick irregular walls onMRI and a core area of reduced signal
suggestive of tumour necrosis
Exclusion criteria:
Tumours in the midline, basal ganglia, cerebellum, or brain stem; more than 1 contrast-
enhancing lesion; substantial, non-contrast-enhancing tumourwith areas suggesting low-
grade glioma with malignant transformation; medical reasons precluding MRI; inability
to give consent; a tumour location that did not enable complete resection; KPS of 60 or
less; renal or liver insufficiency; and a history of previous systemic malignancy
Interventions Intervention:
5-aminolevulinic acid (20 mg/kg body weight; medac, Wedel, Germany) in freshly pre-
pared solutions orally 3 h (range 2 to 4) preoperatively. Solutions were prepared by dis-
solving the contents of a vial (1.5 g) in 50 mL of drinking water. Surgery was done by use
of a modified neurosurgical microscope (OPMI Neuro/NC4 system with fluorescence
kit, Carl Zeiss Surgical GmbH, Oberkochen, Germany), which enabled switching from
conventional white xenon illumination to violet-blue excitation light
Control:
Conventional microsurgery with white light. There was no placebo. For participants
assigned white light, the tumour was resected by use of conventional illumination
Outcomes Primary endpoints: complete tumour resection on MRI (< 72 hours post-operation and
> 1.5 T) and PFS
Secondary endpoints: residual tumour volume, overall survival, type and severity of
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Stummer 2006 (Continued)
neurological deficits after surgery, and toxic effects
Follow-up was at 6 weeks then 3 months and subsequently at 3 monthly intervals until
18 months
Notes Residual tumour was defined as contrast enhancement with a volume more than 0.175
cm3. Progression was defined as the occurrence of a new tumour lesion with a volume
greater than 0.175 cm3, or an increase in residual tumour volume of more than 25%.
Progression-free survival was defined radiologically in the initial trial and by combined
measures in the follow-up paper (radiological criteria as above plus any new tumour or
neurological worsening as defined by an NIHSS score increase over 1)
Adverse events were classified according to the US National Cancer Institute common
toxicity criteria (version 1.0)
The NIHSS was used to measure postoperative deficits at 2 and 7 days after surgery,
radiological progression at 6 weeks, then at 3, 6, 9, 12, 15, and 18 months’ postsurgery
Intercentre consistency was not presented.
The manufacturer of 5-aminolevulinic acid (medac GmbH) was involved in the trial,
and authors received assistance from the sponsor
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Performed independently with a dynamic
allocation algorithm
Allocation concealment (selection bias) Low risk Treatment allocation was communicated
by telephone and fax.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk There was no blinding of surgeons, partic-
ipants, or those involved with treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Neuropathology and neuroradiological as-
sessments were blinded, which is impor-
tant for assessing extent of resection. Clin-
ical outcome assessment was not blinded,
whichwould have affected PFS and adverse
events
Incomplete outcome data (attrition bias)
All outcomes
High risk 13 participants were excluded for major vi-
olations of MRI inclusion criteria. 34 par-
ticipants were excluded for histological cri-
teria. In total, out of 322 randomly assigned
participants, 270 were analysed intention
to treat and 251 per protocol
Selective reporting (reporting bias) High risk Full outcome data were not presented for
survival, PFS, and adverse events (partic-
ularly in the earlier article and less so in
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the follow-up paper). For example, Kaplan-
Meier plots with hazard ratio, 95% con-
fidence interval and log-rank analyses for
the full cohort were not present for sur-
vival, PFS (no hazard ratio with 95% confi-
dence interval), or time to deteriorate in the
NIHSS (subgroup only of those with com-
plete resection). Timing and severity of all
adverse events were not fully documented
(e.g. there were no data on wound infec-
tions or related complications and medical
complications such as pulmonary throm-
boembolism)
Other bias High risk 1. Industry involvement. The sponsor was
involved in the study. It was emphasised
that there was no direct link with data in-
terpretation. In addition, selected authors
received remuneration from the sponsor
Willems 2006
Methods Randomised controlled trial.
Participants were stratified by age (< 45 or ≥ 45) and KPS (≤ 70 or > 70), and they
were evenly randomised to SS (without neuronavigation) or SN (with neuronavigation)
using a computer-generated list with allocation codes in random order, balanced for each
stratum using blocks of 4
Sample size:
Based on the results of a power analysis (details not specified in the paper), the authors
planned to include 182 participants in the study, but the trial was stopped at 45 partic-
ipants after an early pilot analysis
There was no blinding.
Participants Inclusion criteria:
Solitary intracerebral space-occupying lesionwith (partial) contrast enhancement eligible
for surgical debulking with the intention of gross total resection
Exclusion criteria:
Previous neurosurgical treatment or any other known primary tumour elsewhere in the
body
Interventions Intervention:
Neuronavigation was performed with bone fiducial markers. Preoperative magnetic
resonance images were obtained using a 0.5-Tesla system with contrast-enhanced T1
weighted images. Volumetric measurements were performed to assess total lesion vol-
ume. Functional grading was recorded according to the MD Anderson scheme (Sawaya
1998). Planning involved localisation using fiducial markers, trajectory planning, and
segmentation of the tumour boundary. Tools included an infrared pointer or mechani-
cally tracked operating microscope
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Outcomes The primary outcome was extent of resection and survival. Other outcomes were pro-
cedure duration, usefulness of neuronavigation, extent of resection, quality of life, and
postoperative course (including neurological status and adverse events)
Notes There were 3 early deaths in the navigation arm from systemic causes, which with the
low numbers in each arm skewed the results
Interim analysis/abbreviated study.
Definitions:
Postoperative magnetic resonance images were obtained within 72 hours and subject to
volumetric analysis. Clinical assessment was performed postoperatively within 3 days,
1 week, 6 weeks, and 3 months to assess adverse events and neurological status (using
KPS and BI scores). A quality of life questionnaire (EORTCQLQ-C30 and BR-20) was
filled out preoperatively and approximately 3 months after surgery
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The participants were randomised to SS
(without neuronavigation) or SN (with
neuronavigation) using a computer-gen-
erated list with allocation codes in ran-
dom order, balanced for each stratum us-
ing blocks of 4. However, groups were not
evenly distributed at baseline, with more
eloquently located tumours in the stan-
dard surgery arm and histology with more
metastasis in the navigation arm (although
the latter was a variable not able to be de-
termined preoperatively)
Allocation concealment (selection bias) Unclear risk Unclear risk
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk 1 participant was excluded due to an alter-
native diagnosis (meningioma). Postopera-
tive imagingwas only assessed in 34/45 par-
ticipants for tumour volume and 40/45 for
contrast-enhancing volume. Data for qual-
ity of life at 3 months were only reported
on 64.5% of the total eligible population
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Selective reporting (reporting bias) High risk All outcome measures were reported to a
degree. However, full data with suitable
presentation and analysis were not available
for survival (no Kaplan-Meier plots), qual-
ity of life (no statistical analysis), and ad-
verse events (no presentation of numbers of
events)
Other bias High risk The trial was significantly underpowered
and was terminated prematurely. Out of
280 potentially eligible participants, only
46 participants were included, with a
planned target of 182
ASA: American Society of Anesthesiologists
EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer quality of life assessment
KPS: Karnofsky performance score
iMRI: intraoperative magnetic resonance imaging
MRI: magnetic resonance imaging
NIHSS: National Institutes of Health Stroke Scale
PFS: progression-free survival
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Chen 2011 Only abstract available (report is of published conference proceedings). Contacted authors but no reply. Insufficient
information available to fully assess trial for either qualitative or quantitative inclusion
Chen 2012 Only abstract available (report is of published conference proceedings). Contacted authors but no reply. Insufficient
information available to fully assess trial for either qualitative or quantitative inclusion
Czyz 2011 Not a randomised controlled trial
Eljamel 2008 The addition of repetitive photodynamic therapy essentially precludes analysis of this trial as a test of intraoperative
imaging alone
Koc 2008 Prospective study; participants were not randomised.
Rohde 2011 This trial assessed specificity and sensitivity of intraoperative 3D ultrasound as diagnostic test rather than treatment
option
Seddighi 2016 Only abstract available (report is of published conference proceedings). Contacted authors but no reply. Insufficient
information available to fully assess trial for either qualitative or quantitative inclusion
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Stepp 2007 Further report of Stummer 2006 trial; only new data are on spectroscopy and photodynamic therapy
Stummer 2017 A randomised controlled trial on the diagnostic effects of different doses of 5-aminolevulinic acid (clinical, spec-
trophotometric, pathological)
Wu 2003 Author stated that this was not a randomised controlled trial
Wu 2004 Author stated that this was not a randomised controlled trial
Wu 2007 Author stated that this was not a randomised controlled trial
Zhang 2015 Not a randomised controlled trial; “patient selection was based on economic status and the availability of iMRI”’
iMRI: intraoperative magnetic resonance imaging
Characteristics of ongoing studies [ordered by study ID]
NCT00752323
Trial name or title Imaging procedure using ALA in finding residual tumor in grade IV malignant astrocytoma
Methods “Randomised” - possibly diagnostic only trial design
Participants Newly diagnosed and recurrent grade IV glioma
Interventions 2 doses of 5-ALA
Outcomes • In-vivo and pathological fluorescence
• Extent of resection (possibly - not clear from trial notes)
Starting date August 2008
Contact information Andrew Sloan
Notes Case Medical Center, Cleveland, Ohio, USA
NCT00977327
Trial name or title Comparison of neuronavigational systems for resection-control of brain tumors
Methods Randomised trial
Participants Neuroradiological evidence of a brain lesion
Interventions Intraoperative magnetic resonance (PoleStar N-20) versus intraoperative ultrasound (SonoWand)
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Outcomes • Extent of resection
• Cost-effectiveness
Starting date 2009
Contact information Andrew Kanner
Notes Tel Aviv, Israel
NCT01502280 (BALANCE)
Trial name or title Fluorescence-guided surgery for low- and high-grade gliomas
Methods Randomised. Single-blind
Participants Newly diagnosed glioma (high and low grade)
Interventions 5-ALA (Gliolan) versus placebo (ascorbic acid)
Outcomes 1. Volume of residual disease
2. Overall survival
3. 6-month progression-free survival
Starting date November 2010
Contact information Nader Sanai (principal investigator), Norissa Honea (overall contact)
Notes Barrow, Phoenix, Arizona, USA
NCT01798771 (IMAGER)
Trial name or title Intraoperative MRI and 5-ALA Guidance to Improve the Extent of Resection in Brain Tumor Surgery
(IMAGER)
Methods Randomised
Participants Newly diagnosed supratentorial intra-axial brain tumour suspicious for malignant glioma. Deemed resectable
Interventions Intervention: 5-ALA and intraoperative MRI
Control: 5-ALA
Outcomes 1. Extent of resection (according to postoperative MRI within 72 hours)
2. Volumetric extent of resection
3. Progression-free survival
4. Quality of life
5. National Institutes of Health Stroke Scale (NIHSS)
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Starting date February 2013
Contact information Christian Senft
Notes Johann Wolfgang Goethe University Hospitals, Germany
Wu 2014
Trial name or title
Methods Randomised controlled trial.
Randomisation was done by 2 clinical research associates (QY Wu and Ye Wang) at the clinical research
institute, Huashan Hospital, using software specially designed for this trial according to a dynamic allocation
algorithm. This software ensured that no one could predict the randomisation result. This dynamic alloca-
tion algorithm ensured the minimum imbalance between groups after recruiting each participant within 6
covariates with different weights, including tumour grade · 3 (HGG versus LGG), age · 2 (18 to 44, 45 to
64, or 65 to 70 years), KPS · 2 (70 to 90 versus 100), the vicinity of tumour to eloquent brain regions · 1
(non-eloquent versus eloquent), tumour site · 1 (frontal, parietal, temporal, insular, or occipital lobe), and
hemisphere mainly involved by tumour · 1 (non-dominant versus dominant)
Sample size:
The estimated sample size was 320 participants to detect a difference of 15% between the study arms for the
primary endpoint in the full analysis set, given 90% complete power (e.g. probability of rejecting all false null
hypotheses) with an experiment-wise type I error of 0.05
Participants Inclusion criteria:
18 to 70 years of age with newly diagnosed (diagnosed presurgically by board-certified radiologists and
neurosurgeons), untreatedmalignant cerebral glioma (WHOgrade II-IV); with supratentorial lesion involving
the frontal, temporal, parietal, occipital, and/or insular lobe; with or without the lesion in an eloquent area;
with preoperative assessment of attainable radiologically gross total tumour resection (by board-certified
anaesthesiologists and neurosurgeons); and with presurgical KPS score 70
Exclusion criteria:
Recurrent glioma after initial surgical intervention (except needle biopsy); primary glioma with prior radio-
therapy or chemotherapy; lesions of the midline, basal ganglia, cerebellum, or brainstem; renal insufficiency
or hepatic insufficiency; history of malignancy at the body site; other critical tumour location or physical
status that did not enable complete resection of the tumour or restricted life expectancy; and contraindications
precluding iMRI acquisition
Interventions Intervention:
All resections were completed as safely as possible by the consultant surgeons in the same 3-Tesla iMRI
integrated neurosurgical suite by IMRIS Neuro (IMRIS, Inc)
Control:
No further surgery.
Outcomes Primary:
Extent of resection (EOR).
Secondary:
Progression-free survival; overall survival; and surgery-related morbidity
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Wu 2014 (Continued)
Starting date September 2011
Contact information Jinsong Wu
Notes Interim analysis - awaiting full results.
Definitions:
Gross total resection (GTR) was defined as the complete disappearance of all enhancing lesions (T1-weighted)
for HGG and the complete disappearance of all non-enhancing (T2-weighted fluid-attenuated inversion
recovery) lesions for LGG. The EORs were assessed quantitatively in volumetric analyses and stratified as
follows: GTR, 100% resection; subtotal resection, 90% resection; partial resection, 70% resection; and biopsy
5-ALA: 5-aminolevulinic acid
HGG: high-grade glioma
iMRI: intraoperative magnetic resonance imaging
LGG: low-grade glioma
MRI: magnetic resonance imaging
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Karnofsky performance score
Score Definition
100 Normal, no complaints, no evidence of disease
90 Able to carry on normal activity: minor symptoms of disease
80 Normal activity with effort: some symptoms of disease
70 Cares for self: unable to carry on normal activity or active work
60 Requires occasional assistance but is able to care for needs
50 Requires considerable assistance and frequent medical care
40 Disabled: requires special care and assistance
30 Severely disabled: hospitalisation is indicated, death is not imminent
20 Very sick, hospitalisation is necessary: active treatment is necessary
10 Moribund, fatal processes are progressing rapidly
0 Dead
Table 2. WHO performance score
Grade Definition
0 Fully active, able to carry on all pre-disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g.
light house work, office work
2 Ambulatory and capable of all self care, but unable to carry out any work activities. Up and about more than 50% of
waking hours
3 Capable of only limited self care, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry out any self care. Totally confined to bed or chair
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Table 2. WHO performance score (Continued)
5 Dead
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1. MeSH descriptor: [Central Nervous System Neoplasms] explode all trees
#2. ((central nervous system or CNS or brain* or cerebral* or intracerebral or intra-cerebral or intracranial or intra-cranial or spine or
spinal or astrocytic or oligodendroglial or ependymal) near/5 (cancer* or tumor* or tumour* or malignan* or neoplas* or carcinoma*
or metastat*))
#3. MeSH descriptor: [Neoplasms, Neuroepithelial] explode all trees
#4. ((cranial or paraspinal or meninges or haematopoietic system or germ cell or germ-cell or sellar or glioneural or neuroectodermal
or embryonal or neuroepithelial or pineal or choroid plexus or teratoid or rhabdoid) near/5 (tumor* or tumour*))
#5. MeSH descriptor: [Glioma] explode all trees
#6. glioma* or glial* or astrocytoma* or xanthoastrocytoma* or glioblastoma* or gliosarcoma* or oligodendrogli* or oligoastrocyt*
or ependym* or subependym* or astroblastoma* or ganglioglioma* or gangliocytoma* or neurocytoma* or liponeurocytoma* or
pineocytoma* or pineoblastoma* or medulloblastoma* or neuroblastoma* or ganglioneuroblastoma*or medulloepithelioma* or GBM*
#7. #1 or #2 or #3 or #4 or #5 or #6
#8. MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#9. intra operative magnetic resonance imag* or intra-operative magnetic resonance imag* or intra operative MRI or intra-operative
MRI or iMRI or ioMRI or IOMRI or IoMRI or MRI or MRi or NMRI or NMRi or magnetic resonance imag* or tractography
#10. MeSH descriptor: [Ultrasonography] explode all trees
#11. (2D or 3D) near/5 (ultras* or US)
#12. ((intra-operative or intraoperative) near/5 (ultras* or US or IOUS or imag* or navigat* or technolog* or modalit* or eval* or
monitor*))
#13 volumetric reconstruction or Sonowand or SonoWand
#14. MeSH descriptor: [Neuronavigation] this term only
#15. MeSH descriptor: [Surgery, Computer-Assisted] this term only
#16. navigat* or neuronavigat* or neuro-navigat* or image guid*
#17. Brainlab or Stealth
#18. MeSH descriptor: [Monitoring, Intraoperative] explode all trees
#19. MeSH descriptor: [Fluorescence] this term only
#20. MeSH descriptor: [Aminolevulinic Acid] this term only
#21. fluorescen* or immunofluorescen*
#22. aminolevulinic acid or 5-aminolevulinic acid
#23. ALA or 5-ALA or Gliolan
#24. #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
#25. #7 and #24
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Appendix 2. MEDLINE RCT search strategy
1. exp Central Nervous System Neoplasms/
2. ((central nervous system or CNS or brain* or cerebral* or intracerebral or intra-cerebral or intracranial or intra-cranial or spine or
spinal or astrocytic or oligodendroglial or ependymal) adj5 (cancer* or tumor* or tumour* or malignan* or neoplas* or carcinoma* or
metastat*)).mp.
3. exp neoplasms, neuroepithelial/
4. ((cranial or paraspinal or meninges or haematopoietic system or germ cell or germ-cell or sellar or glioneural or neuroectodermal or
embryonal or neuroepithelial or pineal or choroid plexus or teratoid or rhabdoid) adj5 (tumor* or tumour*)).mp.
5. exp Glioma/
6. (glioma* or glial* or astrocytoma* or xanthoastrocytoma* or glioblastoma* or gliosarcoma* or oligodendrogli* or oligoastrocyt* or
ependym* or subependym* or astroblastoma* or ganglioglioma* or gangliocytoma* or neurocytoma* or liponeurocytoma* or pineocy-
toma* or pineoblastoma* or medulloblastoma* or neuroblastoma* or ganglioneuroblastoma*or medulloepithelioma* or GBM*).mp.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp Magnetic Resonance Imaging/
9. (intra operative magnetic resonance imag* or intra-operative magnetic resonance imag* or intra operative MRI or intra-operative
MRI or iMRI or ioMRI or IOMRI or IoMRI or MRI or MRi or NMRI or NMRi or magnetic resonance imag* or tractography).mp.
10. exp Ultrasonography/
11. ((2D or 3D) adj5 (ultras* or US)).mp.
12. ((intra-operative or intraoperative) adj5 (ultras* or US or IOUS or imag* or navigat* or technolog* or modalit* or eval* or
monitor*)).mp.
13. (volumetric reconstruction or Sonowand or SonoWand).mp.
14. Neuronavigation/
15. Surgery, Computer-Assisted/
16. (navigat* or neuronavigat* or neuro-navigat* or image guid*).mp.
17. (Brainlab or Stealth).mp.
18. exp Monitoring, Intraoperative/
19. Fluorescence/
20. Aminolevulinic Acid/
21. (fluorescen* or immunofluorescen*).mp.
22. (aminolevulinic acid or 5-aminolevulinic acid).mp.
23. (ALA or 5-ALA or Gliolan).mp.
24. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. 7 and 24
26. randomized controlled trial.pt.
27. controlled clinical trial.pt.
28. randomized.ab.
29. placebo.ab.
30. clinical trials as topic.sh.
31. randomly.ab.
32. trial.ti.
33. 26 or 27 or 28 or 29 or 30 or 31 or 32
34. (animals not (humans and animals)).sh.
35. 33 not 34
36. 25 and 35
Key
mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier
ab = abstract
sh = subject heading
ti = title
pt = publication type
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Appendix 3. Embase RCT strategy
1. exp central nervous system tumor/
2. ((central nervous system or CNS or brain* or cerebral* or intracerebral or intra-cerebral or intracranial or intra-cranial or spine or
spinal or astrocytic or oligodendroglial or ependymal) adj5 (cancer* or tumor* or tumour* or malignan* or neoplas* or carcinoma* or
metastat*)).mp.
3. exp neuroepithelioma/
4. ((cranial or paraspinal or meninges or haematopoietic system or germ cell or germ-cell or sellar or glioneural or neuroectodermal or
embryonal or neuroepithelial or pineal or choroid plexus or teratoid or rhabdoid) adj5 (tumor* or tumour*)).mp.
5. exp glioma/
6. (glioma* or glial* or astrocytoma* or xanthoastrocytoma* or glioblastoma* or gliosarcoma* or oligodendrogli* or oligoastrocyt* or
ependym* or subependym* or astroblastoma* or ganglioglioma* or gangliocytoma* or neurocytoma* or liponeurocytoma* or pineocy-
toma* or pineoblastoma* or medulloblastoma* or neuroblastoma* or ganglioneuroblastoma*or medulloepithelioma* or GBM*).mp.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp nuclear magnetic resonance imaging/
9. (intra operative magnetic resonance imag* or intra-operative magnetic resonance imag* or intra operative MRI or intra-operative
MRI or iMRI or ioMRI or IOMRI or IoMRI or MRI or MRi or NMRI or NMRi or magnetic resonance imag* or tractography).mp.
10. exp echography/
11. ((2D or 3D) adj5 (ultras* or US)).mp.
12. ((intra-operative or intraoperative) adj5 (ultras* or US or IOUS or imag* or navigat* or technolog* or modalit* or eval* or
monitor*)).mp.
13. (volumetric reconstruction or Sonowand or SonoWand).mp.
14. neuronavigation/
15. computer assisted surgery/
16. (navigat* or neuronavigat* or neuro-navigat* or image guid*).mp.
17. (Brainlab or Stealth).mp.
18. exp intraoperative monitoring/
19. fluorescence/
20. aminolevulinic acid/
21. (fluorescen* or immunofluorescen*).mp.
22. (aminolevulinic acid or 5-aminolevulinic acid).mp.
23. (ALA or 5-ALA or Gliolan).mp.
24. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. 7 and 24
26. crossover procedure/
27. double-blind procedure/
28. randomized controlled trial/
29. single-blind procedure/
30. random*.mp.
31. factorial*.mp.
32. (crossover* or cross over* or cross-over*).mp.
33. placebo*.mp.
34. (double* adj blind*).mp.
35. (singl* adj blind*).mp.
36. assign*.mp.
37. allocat*.mp.
38. volunteer*.mp.
39. 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38
40. 25 and 39
41. (exp animal/ or nonhuman/ or exp animal experiment/) not human/
42. 40 not 41
Key
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mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier
ab=abstract
sh=subject heading
ti=title
pt=publication type
Appendix 4. MEDLINE economic search strategy
1. exp Central Nervous System Neoplasms/
2. ((central nervous system or CNS or brain* or cerebral* or intracerebral or intra-cerebral or intracranial or intra-cranial or spine or
spinal or astrocytic or oligodendroglial or ependymal) adj5 (cancer* or tumor* or tumour* or malignan* or neoplas* or carcinoma* or
metastat*)).mp.
3. exp neoplasms, neuroepithelial/
4. ((cranial or paraspinal or meninges or haematopoietic system or germ cell or germ-cell or sellar or glioneural or neuroectodermal or
embryonal or neuroepithelial or pineal or choroid plexus or teratoid or rhabdoid) adj5 (tumor* or tumour*)).mp.
5. exp Glioma/
6. (glioma* or glial* or astrocytoma* or xanthoastrocytoma* or glioblastoma* or gliosarcoma* or oligodendrogli* or oligoastrocyt* or
ependym* or subependym* or astroblastoma* or ganglioglioma* or gangliocytoma* or neurocytoma* or liponeurocytoma* or pineocy-
toma* or pineoblastoma* or medulloblastoma* or neuroblastoma* or ganglioneuroblastoma*or medulloepithelioma* or GBM*).mp.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp Magnetic Resonance Imaging/
9. (intra operative magnetic resonance imag* or intra-operative magnetic resonance imag* or intra operative MRI or intra-operative
MRI or iMRI or ioMRI or IOMRI or IoMRI or MRI or MRi or NMRI or NMRi or magnetic resonance imag* or tractography).mp.
10. exp Ultrasonography/
11. ((2D or 3D) adj5 (ultras* or US)).mp.
12. ((intra-operative or intraoperative) adj5 (ultras* or US or IOUS or imag* or navigat* or technolog* or modalit* or eval* or
monitor*)).mp.
13. (volumetric reconstruction or Sonowand or SonoWand).mp.
14. Neuronavigation/
15. Surgery, Computer-Assisted/
16. (navigat* or neuronavigat* or neuro-navigat* or image guid*).mp.
17. (Brainlab or Stealth).mp.
18. exp Monitoring, Intraoperative/
19. Fluorescence/
20. Aminolevulinic Acid/
21. (fluorescen* or immunofluorescen*).mp.
22. (aminolevulinic acid or 5-aminolevulinic acid).mp.
23. (ALA or 5-ALA or Gliolan).mp.
24. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. 7 and 24
26. economics/
27. exp “costs and cost analysis”/
28. economics, dental/
29. exp “economics, hospital”/
30. economics, medical/
31. economics, nursing/
32. economics, pharmaceutical/
33. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
34. (expenditure$ not energy).ti,ab.
35. (value adj1 money).ti,ab.
36. budget$.ti,ab.
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37. 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
38. ((energy or oxygen) adj cost).ti,ab.
39. (metabolic adj cost).ti,ab.
40. ((energy or oxygen) adj expenditure).ti,ab.
41. 38 or 39 or 40
42. 37 not 41
43. letter.pt.
44. editorial.pt.
45. historical article.pt.
46. 43 or 44 or 45
47. 42 not 46
48. Animals/
49. Humans/
50. 48 not (48 and 49)
51. 47 not 50
52. 25 and 51
Key
mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier
ab = abstract
sh = subject heading
ti = title
pt = publication type
Appendix 5. Embase economic search strategy
1. exp central nervous system tumor/
2. ((central nervous system or CNS or brain* or cerebral* or intracerebral or intra-cerebral or intracranial or intra-cranial or spine or
spinal or astrocytic or oligodendroglial or ependymal) adj5 (cancer* or tumor* or tumour* or malignan* or neoplas* or carcinoma* or
metastat*)).mp.
3. exp neuroepithelioma/
4. ((cranial or paraspinal or meninges or haematopoietic system or germ cell or germ-cell or sellar or glioneural or neuroectodermal or
embryonal or neuroepithelial or pineal or choroid plexus or teratoid or rhabdoid) adj5 (tumor* or tumour*)).mp.
5. exp glioma/
6. (glioma* or glial* or astrocytoma* or xanthoastrocytoma* or glioblastoma* or gliosarcoma* or oligodendrogli* or oligoastrocyt* or
ependym* or subependym* or astroblastoma* or ganglioglioma* or gangliocytoma* or neurocytoma* or liponeurocytoma* or pineocy-
toma* or pineoblastoma* or medulloblastoma* or neuroblastoma* or ganglioneuroblastoma*or medulloepithelioma* or GBM*).mp.
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp nuclear magnetic resonance imaging/
9. (intra operative magnetic resonance imag* or intra-operative magnetic resonance imag* or intra operative MRI or intra-operative
MRI or iMRI or ioMRI or IOMRI or IoMRI or MRI or MRi or NMRI or NMRi or magnetic resonance imag* or tractography).mp.
10. exp echography/
11. ((2D or 3D) adj5 (ultras* or US)).mp.
12. ((intra-operative or intraoperative) adj5 (ultras* or US or IOUS or imag* or navigat* or technolog* or modalit* or eval* or
monitor*)).mp.
13. (volumetric reconstruction or Sonowand or SonoWand).mp.
14. neuronavigation/
15. computer assisted surgery/
16. (navigat* or neuronavigat* or neuro-navigat* or image guid*).mp.
17. (Brainlab or Stealth).mp.
18. exp intraoperative monitoring/
19. fluorescence/
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20. aminolevulinic acid/
21. (fluorescen* or immunofluorescen*).mp.
22. (aminolevulinic acid or 5-aminolevulinic acid).mp.
23. (ALA or 5-ALA or Gliolan).mp.
24. 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. 7 and 24
26. Health Economics/
27. exp Economic Evaluation/
28. exp Health Care Cost/
29. pharmacoeconomics/
30. 26 or 27 or 28 or 29
31. (econom$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
32. (expenditure$ not energy).ti,ab.
33. (value adj2 money).ti,ab.
34. budget$.ti,ab.
35. 31 or 32 or 33 or 34
36. 30 or 35
37. letter.pt.
38. editorial.pt.
39. note.pt.
40. 37 or 38 or 39
41. 36 not 40
42. (metabolic adj cost).ti,ab.
43. ((energy or oxygen) adj cost).ti,ab.
44. ((energy or oxygen) adj expenditure).ti,ab.
45. 42 or 43 or 44
46. 41 not 45
47. 25 and 46
48. (exp animal/ or nonhuman/ or exp animal experiment/) not human/
49. 47 not 48
Key
mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier
ab=abstract
sh=subject heading
ti=title
pt=publication type
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